Figure 5.
NDV(F3aa)-NS1 suppresses tumor growth and promotes mouse survival in a syngeneic murine melanoma model. (a) Short-term tumor growth in B16-F10 melanoma-bearing mice treated with recombinant Newcastle disease viruses (NDVs) at 7 days. Mice were injected in the right posterior foot pad with 105 of cultured B16-F10 cells, and 7 days later were treated with 5 × 106 of the indicated viruses or phosphate-buffered saline (PBS) for a total of four injections. All eight mice from the control group and six randomly chosen mice from each virus group were killed on day 25 for immune studies (see Figure 6). (b) Short-term tumor growth in mice treated at 10 days. Starting on day 10 after tumor cell line injection, the mice were treated every other day with a total of six doses of 5 × 106 pfu of the indicated virus or PBS. When the largest tumors reached 8 mm in length, all of the animals were killed. (c) Long-term tumor growth follow-up in the treated mice. The remaining seven animals from each group in a were continued to be followed for 120 days, with tumor measurements being recorded every 2 days. (d) Summary of 120-day survival of the animals treated in a. Mice were killed when the tumors reached 8 mm in length. For experimental groups, only the mice included in the long-term study (n = 7 for each group) were included in the analysis (*P < 1 × 10−6).